We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Prion Proteins Might Not Cause Creutzfeld-Jacob

By HospiMedica staff writers
Posted on 24 Apr 2006
A new study indicates that abnormal prion proteins (PrP) might not be the infectious agent for variant Creutzfeld-Jacob disease (vCJD). More...


Since the first outbreak of bovine spongiform encephalopathy (BSE) in cattle and vCJD in humans, researchers have tried to understand how an abnormal variation of a normal protein can trigger an infectious disease.

Individual people and animals have different levels of genetic susceptibility to the disease. In a study published in the March 2006 Journal of Pathology, researchers investigated the transportation of prion protein across the intestinal mucosa of scrapie-sensitive and scrapie-resistant sheep. Scrapie is the sheep form of the disease. They found that when they injected abnormal PrP into the sheep's gut it was equally absorbed by all sheep. They concluded that the resistance was not achieved by blocking uptake of the abnormal proteins.

The researchers loaded a small area of the sheep's gut with a fluid mixture containing 0.5g of scrapie-infected brain containing a large amount of the disease-specific variant of the PrP. The abnormal PrP was taken up by villi but not by the Peyer's patches that are believed to be the places where animals amplify the infectious agent.

A mixture of disease-specific PrP predigested with standard stomach contents was injected into the gut, but no PrP was transferred to the villi. Western Blot analysis of the mixture showed that only a very small amount of the PrP had survived. Lead author Martin Jeffrey, Ph.D., of the Veterinary Laboratories Agency (Lasswade, UK), observed, "As sheep become infected, the theoretical probability that this is due to an invisible sub-fraction of digestion-resistant PrP molecules is unlikely.” He questions whether PrP is really infectious or whether it is really just a secondary marker indicating the presence of the scrapie agent.

Dr. Jeffrey said that if the infection were acquired from the mouth, the first tissues to accumulate infectivity would be the lymph nodes in the throat or the tonsils. This is not seen in animals and there is no reason to believe it would be so in humans.



Related Links:
Veterinary Laboratories Agency

Gold Member
12-Channel ECG
CM1200B
Radiology Monitor
MDNC-6121 Barco Nio Color 5.8MP
Surgical Dressing
ALLEVYN Ag+ SURGICAL
Multi-Chamber Washer-Disinfector
WD 390
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: New findings show that chemotherapy plus immunotherapy before surgery produced greater tumor destruction than immunotherapy alone in head and neck cancer patients (Image Credit: Adobe Stock)

Combination Therapy Before Surgery Drives Stronger Tumor Reduction in Head and Neck Cancer

Patients with head and neck cancer who are scheduled for surgery often face a waiting period with limited treatment, creating an opportunity to reduce viable tumor burden before the operation.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.